CU20140114A7 - Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné - Google Patents

Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné

Info

Publication number
CU20140114A7
CU20140114A7 CU2014000114A CU20140114A CU20140114A7 CU 20140114 A7 CU20140114 A7 CU 20140114A7 CU 2014000114 A CU2014000114 A CU 2014000114A CU 20140114 A CU20140114 A CU 20140114A CU 20140114 A7 CU20140114 A7 CU 20140114A7
Authority
CU
Cuba
Prior art keywords
acne
odd
composition containing
dialil
pyrfenidone
Prior art date
Application number
CU2014000114A
Other languages
English (en)
Inventor
Borunda Juan Socorro Armendáriz
Castro José Agustín Rogelio Magaña
Santoyo Pedro Peña
Cervantes Laura Vázquez
Original Assignee
Cell Therapy And Technology S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Technology S A De C V filed Critical Cell Therapy And Technology S A De C V
Publication of CU20140114A7 publication Critical patent/CU20140114A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe una composición tópica semisólida conteninedo Pirfenidona y un antimicrobiano/antiséptico como Dialil Óxido de Disulfuro Modificado (ODD-M) y su proceso de fabricación, que ofrece ventajas sobre otras formas farmacéuticas de administración cutánea conocidas en el estado de la técnica, que es útil como agente anti-fibrótico, anti-inflamatorio y antiséptico en la prevención, tratamiento y reversión del acné y las lesiones post-acnéicas. Dicha composición también es útil para dismunir el tono rojizo de la piel, para detener la formación de nuevos brotes de acné, para revertir los brotes ya existentes y para regenerar la piel dañada a consecuencia del acné.
CU2014000114A 2012-03-28 2014-09-26 Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné CU20140114A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012003694A MX346763B (es) 2012-03-28 2012-03-28 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
PCT/MX2013/000027 WO2013147577A1 (es) 2012-03-28 2013-02-27 Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné

Publications (1)

Publication Number Publication Date
CU20140114A7 true CU20140114A7 (es) 2015-01-29

Family

ID=48096131

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000114A CU20140114A7 (es) 2012-03-28 2014-09-26 Compisición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné

Country Status (22)

Country Link
US (7) US20150148382A1 (es)
EP (1) EP2832354A1 (es)
JP (1) JP2015513359A (es)
KR (1) KR20140146144A (es)
CN (1) CN104334171A (es)
AR (1) AR090457A1 (es)
AU (1) AU2013240709A1 (es)
CA (1) CA2868729C (es)
CL (1) CL2014002591A1 (es)
CO (1) CO7071140A2 (es)
CU (1) CU20140114A7 (es)
DO (1) DOP2014000218A (es)
EA (1) EA201401031A1 (es)
IL (1) IL234816A0 (es)
IN (1) IN2014DN08067A (es)
MA (1) MA20150062A1 (es)
MX (1) MX346763B (es)
PH (1) PH12014502154A1 (es)
SG (1) SG11201406035VA (es)
TN (1) TN2014000396A1 (es)
UY (1) UY34700A (es)
WO (1) WO2013147577A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN106491517B (zh) * 2016-11-23 2019-12-06 佛山科学技术学院 吡非尼酮pva水凝胶的制备方法及吡非尼酮pva水凝胶
US20180360751A1 (en) * 2017-06-19 2018-12-20 Advanced Fibrosis Research LLC Transdermal cream for treating Dupuytren's Contracture
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
EP4003256B1 (en) 2019-07-30 2025-12-10 The Government of The United States, as Represented by The Secretary of The Army Layered composite for scar treatment and prevention

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
GB1458048A (en) 1972-12-18 1976-12-08 Affiliated Med Res Pharmaceutical composition
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128433A (en) 1975-04-30 1976-11-09 Ajinomoto Co Inc A herbicide
SE430609B (sv) 1976-12-21 1983-11-28 Sca Development Ab Sett att ur cellulosaderivat framstella absorberande material
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
ATE224712T1 (de) 1993-05-07 2002-10-15 Solomon B Margolin Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
CZ293747B6 (cs) 1995-12-21 2004-07-14 Pfizer Inc. Vodný farmaceutický roztok vhodný pro injekční podávání hostiteli a jeho použití
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
ATE266405T1 (de) 1998-03-17 2004-05-15 Solomon B Margolin Topische antiseptische zusammenstellungen und methoden
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
WO2000016775A1 (en) 1998-09-18 2000-03-30 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (es) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20030103941A1 (en) 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
CH696420A5 (de) 2002-09-13 2007-06-15 Mepha Ag Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung.
TW200501952A (en) 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
WO2004078207A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
US20060198823A1 (en) 2003-04-04 2006-09-07 Blatt Lawrence M Compositions and methods for treating viral infections
US8222299B2 (en) * 2003-05-23 2012-07-17 Allium Vitalis Incorporated Organosulfur prodrugs for the prevention and treatment of infectious diseases
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20070258946A1 (en) 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
CN100542532C (zh) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
EP2305696A3 (en) 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20110034495A1 (en) 2005-11-23 2011-02-10 Intermune, Inc. Method of Modulating Stress-Activated Protein Kinase System
EP1973525B1 (en) 2005-12-05 2014-04-30 RBA Pharma Inc. Emulsion-containing medical articles
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
EP2134683A2 (en) 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
CA2679700A1 (en) 2007-03-02 2008-09-12 Talia Miron Mercaptopurine derivatives as anticancer agents
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
AU2008335717A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CN101972236A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN101972225A (zh) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的凝胶组合物
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
CA2827373C (en) 2011-02-15 2019-05-14 Epi Health, Llc Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
CN102670600A (zh) 2011-03-12 2012-09-19 赵海静 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用
CN102670632A (zh) 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
US9241921B2 (en) 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
WO2013181691A1 (en) 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
EA201590006A1 (ru) 2012-06-12 2015-05-29 Ф. Хоффманн-Ля Рош Аг Комбинация терапевтических средств для лечения инфекции, вызванной вирусом гепатита c
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2905587A1 (en) 2013-03-15 2014-09-18 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
MX352342B (es) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos.
CN103550242B (zh) 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
GB201508419D0 (en) 2015-05-15 2015-07-01 Cambridge Entpr Ltd Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
KR20180093932A (ko) 2015-12-16 2018-08-22 다이이찌 산쿄 가부시키가이샤 창상 치료제
JOP20170113B1 (ar) 2016-05-09 2023-03-28 Bayer Pharma AG مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
MX364040B (es) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.

Also Published As

Publication number Publication date
US20200061040A1 (en) 2020-02-27
TN2014000396A1 (en) 2015-12-21
IN2014DN08067A (es) 2015-05-01
EA201401031A1 (ru) 2015-05-29
AU2013240709A1 (en) 2014-11-06
CA2868729A1 (en) 2013-10-03
PH12014502154A1 (en) 2014-12-10
MA20150062A1 (fr) 2015-02-27
US20210346360A1 (en) 2021-11-11
US20250367177A1 (en) 2025-12-04
UY34700A (es) 2013-10-31
AR090457A1 (es) 2014-11-12
US20180214434A1 (en) 2018-08-02
US9949959B2 (en) 2018-04-24
MX346763B (es) 2017-03-31
JP2015513359A (ja) 2015-05-11
SG11201406035VA (en) 2014-11-27
CO7071140A2 (es) 2014-09-30
US20150148382A1 (en) 2015-05-28
US11013727B2 (en) 2021-05-25
WO2013147577A1 (es) 2013-10-03
EP2832354A1 (en) 2015-02-04
US11766426B2 (en) 2023-09-26
CN104334171A (zh) 2015-02-04
US20160228424A1 (en) 2016-08-11
IL234816A0 (en) 2014-12-31
DOP2014000218A (es) 2014-12-15
US20240216350A1 (en) 2024-07-04
MX2012003694A (es) 2013-09-30
CL2014002591A1 (es) 2015-01-16
CA2868729C (en) 2020-10-20
KR20140146144A (ko) 2014-12-24

Similar Documents

Publication Publication Date Title
DOP2014000218A (es) Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
MX2015010190A (es) Metodos de tratamiento topico para infecciones microbianas.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
ECSP20010477A (es) Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
JP2017537936A5 (es)
ECSP109960A (es) Gel conteniendo pirfenidona
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
DOP2016000007A (es) Pirazolpiridinas sustituidas
AR092199A1 (es) Composicion antiseptica, antiseborreica y exfoliante para eliminar o prevenir el acne
TN2015000282A1 (fr) Composition dermatologique antimicrobienne topique
FR2978665B1 (fr) Composition antiseptique
ES3063839T3 (en) Composition for external skin use for inflammatory diseases
CL2011000183A1 (es) Uso de una composicion de extracto seco de buddleja globosa, para preparar un fitofarmaco, medicamento o un nutraceutico para prevenir o tratar trastornos gastrointestinales causados por tratamientos antimicrobianos.
ES2531407T3 (es) Composiciones dermatológicas que contienen una asociación de lípidos peroxidados y zinc y sus utilizaciones particularmente en el tratamiento del herpes
BR112015030352A2 (pt) composições que compreendem um álcool aromático e um antagonista do trpv-1 e usos dessas composições
MX2015008104A (es) Uso de pidotimod para tratar la psoriasis.
CY1124107T1 (el) Συνδυασμος αδαπαλενης και υπεροξειδιου του βενζολιου για τη θεραπευτικη αντιμετωπιση της σοβαρης ακμης
MX365920B (es) Uso de un extracto vegetal para la pérdida de pelo.
MX2019005372A (es) Preparacion medica externa para la piel.
CR20160116A (es) Método para tratar onicomicosis con hidroxipropil quitasano
PE20210927A1 (es) Composiciones antimicrobianas con agentes efervescentes
UA104461U (uk) Медикаментозна збовтувана композиція для топічної терапії звичайних вугрів